



PTO/SB/08a(04-07)
Approved for use through 7/31/2006. OMB 0651-0031
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			
<i>Complete if Known</i>			
Application Number		10/522,207	
Filing Date		January 13, 2005	
First Named Inventor		Ali et al.	
Art Unit		1625	
Examiner Name		Chang, Celia C.	
Sheet	1	of	3
Attorney Docket No: AC-22-US			

US PATENT DOCUMENTS					
Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Filing Date If Appropriate
		4,639,463	01-1987	Rosner et al.	
		5,798,366	8-1998	Platt et al.	
		6,426,198	7-2002	Carstea et al.	
		6,495,570	12-2002	Jacob et al.	
		6,683,076	01-2004	Walkley et al.	
		20010044453	11-2001	Jacob et al.	
		20060058349	03-2006	Hussein et al.	
		20060074107	04-2006	Butters et al.	
		20060111400	05-2006	Hussein et al.	
		20070112028	05-2007	Orchard et al.	
		20070259918	11-2007	Orchard	
		20080234324	09-2008	Scopes et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	T ²
		WO 92/00277	09 Jan 1992	Nippon Shinyaku Co., Ltd.	
		WO 94/26714	24 Nov 1994	G.D. Searle & Co.	
		WO 98/02161	22 Jan 1998	Universiteit Van Amsterdam	
		WO 98/30219	16 Jul 1998	Monsanto Company	
		WO 99/24401	20 May 1999	G.D. Searle & Co.	
		WO 00/33843	15 Jun 2000	G.D. Searle & Co., et al.	
		WO 00/56334	28 Sep 2000	The Trustees of Boston College et al.	
		WO 00/62780	26 Oct 2000	Oxford Glycosciences (UK) Ltd.	
		WO 01/10429	15 Feb 2001	Zitzmann et al.	
		WO 04/007453	22 Jan 2004	Oxford Glycosciences (UK) Ltd.	
		WO 04/007454	22 Jan 2004	Oxford Glycosciences (UK) Ltd.	
		WO 04/111001	23 Dec 2004	Oxford Glycosciences (UK) Ltd.	
		WO 04/111002	23 Dec 2004	Oxford Glycosciences (UK) Ltd.	
		WO 05/068426	28 Jul 2005	Cell-Tech R&D Limited	
		EP 0491041	24 Jun 1992	Nippon Shinyaku Co. Ltd.	
		EP 0536402	14 Apr 1993	Nippon Shinyaku Co. Ltd.	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
(Use as many sheets as necessary)			
Sheet	2	of	3
Attorney Docket No: AC-22-US			

		EP 698102	01 Mar 2006	Roche Diagnostics GmbH	
		JP 3-24057	01 Feb 1991	Tosoh Corp.	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
		ABE et al., Induction of glucosylceramide synthase by synthase inhibitors and ceramide, 333-341, (1996)			
		BUTTERS et al., Therapeutic applications of imino sugars in lysosomal storage disorders, Current Topics in Medicinal Chemistry, 3, 561-574 (2003)			
		CAREY, Organic Chemistry, 2nd Edition, Pages 28-29, 268-271			
		CHEN et al., Abnormal transport along the lysosomal pathway in mucolipidosis, type IV disease, Proc. Natl. Acad. Sci. USA, 95, 6373-6378, (1998)			
		GREENE, Protective groups in organic synthesis, Wiley-Interscience Publication, pages: cover, 10, 11, 29 (1982)			
		MELLOR, High-performance cation-exchange chromatography and pulsed amperometric detection for the separation, detection, and quantitation of N-alkylated imino sugars in biological samples, Analytical Biochemistry, XP-001055984, 284, 136-142 (2000)			
		MERZAK et al., Gangliosides modulate proliferation, migration, and invasiveness of human brain tumor cells <i>in vitro</i>, Mol. & Chem. Neuropathology, 24, 121-135 (1995)			
		MORRISON et al., Organic Chemistry, 5th Edition, Pages 138-141			
		OVERKLEEF et al., Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase, J. of Bio. Chem, 273(41), 26522-26527 (1998)			
		PLATT et al., N-Butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis, 269(11), 8362-8365 (1994)			
		SCHALLER et al., Total synthesis of (+)- and (-)-1-deoxynojirimycin (1,5-dideoxy-1,5-imino-D-and L-glucitol) and of (+)- and (-)-1-deooxydonojirimycin(1,5-dideoxy-1,5-imino-D and L-iditol) via furoisoxazoline-3-aldehydes, Carbohydrate Res., 314, 25-35, (1998)			
		SCHNEIDER, GM1 ganglioside in the treatment of Parkinson's Disease, Ann. NY Acad. Sci., 845, 363-373 (1998)			
		TYLE, Iontophoretic devices for drug delivery, Pharm. Res., 3, 318-326 (1986)			

EXAMINER**DATE CONSIDERED**

Substitute for form 1449A/PTO			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
(Use as many sheets as necessary)			
<i>Complete if Known</i>			
Application Number		10/522,207	
Filing Date		January 13, 2005	
First Named Inventor		Ali et al.	
Art Unit		1625	
Examiner Name		Chang, Celia C.	
Sheet	3	of	3
Attorney Docket No: AC-22-US			

		VAN DER SPOEL et al., Reversible infertility in male mice after oral administration of alkylated imino sugars: A nonhormonal approach to male contraception, Proc. Natl. Acac. Sci. USA, 99(26), 17173-17178 (2002)	
--	--	--	--

EXAMINER**DATE CONSIDERED**